澳大利亚生物制药公司Telix将Nasdaq ADR列入清单,方便美国投资者查阅。 Australian biopharmaceutical firm Telix files Nasdaq ADR listing for easier US investor access.
澳大利亚生物制药公司Telix制药公司向证交会提交了表格20-F登记表,以列入美国在Nasdaq的存款股份。 Telix Pharmaceuticals, an Australian biopharmaceutical firm, has filed a Form 20-F registration with the SEC to list American Depository Shares on the Nasdaq. 这个二级ADR方案旨在为美国投资者提供更容易获得Telix股份的机会,扩大其全球投资者基础,并提高生物制药市场的能见度。 This Level II ADR program aims to provide U.S. investors easier access to Telix shares, broaden its global investor base, and enhance visibility in the biopharmaceutical market. 该公司将不发行新股票或筹集资本,并将保持其在澳大利亚证券交易所的主要上市地位。 The company will not issue new shares or raise capital and will maintain its primary listing on the Australian Securities Exchange.